The patient population nuances for Hemlibra® are under investigation in five distinct clinical trials, including one trial assessing its use for von Willebrand disease (vWD) instead of its original indication, Hemophilia A.76, 77, 78, 79, 80, 81Similarly, the recently approved gene therapy RoctavianTM is further investigated in five ongoing clinical trials, all dedicated to studying its efficacy in specific Hemophilia A patient subpopulations. This evidence concerns the gene VWF and platelet-type von Willebrand disease.